



Enduring Hearts and Natera Announce Partnership to Advance Pediatric Heart Transplant Research

[Atlanta, GA] Enduring Hearts, a nonprofit organization dedicated to funding innovative research that improves the quality of life and longevity for children living with transplanted hearts, is proud to announce a partnership with Natera, a leader in cell-free DNA (cfDNA) and genetic testing, to advance pediatric heart transplant research, support family programs, and sponsor key events. This collaboration brings together two organizations committed to advancing early interventions and enhancing patient outcomes.

Over 500 pediatric heart transplants occur annually in the U.S., with the median lifespan of these transplants lasting less than 20 years, highlighting the urgency for innovative solutions. Enduring Hearts' research focus areas include reducing cardiac allograft vasculopathy (CAV) and rejection, identifying and developing pre-transplant strategies with new innovations, and implementing evidence-based strategies to improve medication adherence for recipients during adolescence. Central to Enduring Hearts' impact is the guidance of its Scientific Advisory Committee (SAC), comprised of leading cardiologists, transplant surgeons, and researchers. The SAC evaluates and selects the most promising studies for funding, ensuring alignment with the organization's goal of transforming pediatric heart transplant care.

Natera has transformed various medical fields such as reproductive health, cancer care and organ health with its cutting-edge testing technologies. For heart transplant recipients, the company offers its Prospera™ Heart blood test, which uses donor-derived cell-free DNA (dd-cfDNA) technology to enable early detection of possible organ rejection without the need for traditional biopsies.

"At Enduring Hearts, we are committed to advancing the field of pediatric heart transplantation through groundbreaking research and innovation. By collaborating with aligned partners like Natera, we are combining efforts to transform the future of medical science," said Lynda Lee Smith, Enduring Hearts Chief Executive Officer.

"We wholeheartedly support the mission of Enduring Hearts to transform care for pediatric patients and foster research that prioritizes patient comfort and long-term health," said Sangeeta Bhorade, MD, Natera Chief Medical Officer of Organ Health. "This collaboration is a powerful testament to the shared commitment of Enduring Hearts and Natera to invest in innovative solutions that protect health, inform early interventions, and ultimately lead to longer, healthier lives for children with transplanted hearts."

About Enduring Hearts

Enduring Hearts is the only national nonprofit organization that funds research aimed at improving the quality of life and longevity of pediatric heart transplant recipients. By advancing studies that address the challenges of heart transplant longevity, Enduring Hearts seeks to transform the

standard of care for young patients and their families. Since 2013, Enduring Hearts has funded 72 research grants at 43 combined national and international institutions for a total investment of \$11M towards pediatric heart transplant research. For more information, visit www.enduringhearts.org.

About Natera

Natera™ is a global leader in advancing personalized genetic testing and diagnostics, leveraging innovative cell-free DNA (cfDNA) technology to transform care in women's health, oncology, and organ health. Through solutions like the Prospera™ Heart test, Natera provides noninvasive, accurate assessments of transplanted organ health, enabling early detection of potential rejection. With a commitment to enhancing patient outcomes, Natera's work is supported by over 250 peer-reviewed studies and operates in ISO-certified and CLIA-accredited laboratories. For more information, visit www.natera.com.

Media Contact:

Jazmine Charles
Marketing & Communications Manager
Enduring Hearts
<mailto:jcharles@enduringhearts.org>